LEO Pharma appoints new executive vice president
pharmafile | February 29, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | LEO Pharma, supply chain
From March Anders Spohr will take over the position of executive vice president for global product supply at LEO Pharma.
Spohr was only recently appointed senior vice president of LEO Pharma but soon will assume his new position overseeing LEO Pharma’s global production.
From his previous career with Novo Nordisk and Novozymes, Spohr has gained extensive experience in managing and governing global production. As executive vice president of global product supply, it will be his task to ensure flexible, efficient and streamlined production processes to support LEO Pharma’s operations in more than 100 countries worldwide.
Spohr worked for Novo Nordisk from 1997 to 2000, when he started working for Novozymes, which at that point separated from Novo Nordisk to become a company in its own right. During his 11 years at Novozymes, Spohr was stationed for a period at the company’s offices in North Carolina, US. His latest position in Novozymes, before joining LEO Pharma, was vice president of supply chain management.
Spohr takes over the position as executive vice president from John Mehlbye, who is retiring but will be on the LEO Foundation board.
Related Content

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …

LEO Pharma initiates phase 2a trial of delgocitinib cream for rare skin condition
LEO Pharma has initiated a phase 2a trial investigating delgocitinib cream in adults with mild-to-severe …
MHRA Grants Marketing Authorisation for LEO Pharma’s Anzupgo® ▼(delgocitinib) cream in Great Britain
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation in Great Britain …






